Thumbi Ndung'u, BVM, PhD discussed the safety and partial virologic control observed in a Phase 2a trial using broadly neutralizing antibodies and vesatolimod in HIV treatment interruption.
Thumbi Ndung'u, BVM, PhD
Advertisement
Scientific Director of the HIV Pathogenesis Programme and Professor of HIV/TB Research at the University of KwaZulu-Natal.
Articles by Thumbi Ndung'u, BVM, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
A Mild Avian Influenza Season Ahead?
2
Top Infectious Disease News Stories Week of October 25-October 31
3
Qpex Biopharma’s New President Wants More Push-Pull Incentives, Opportunities for Young US Scientists
4
